Altered balance between effector T cells and FOXP3 + HELIOS + regulatory T cells after thymoglobulin induction in kidney transplant recipients

Department of Surgery, University of California, San Francisco, CA, USA  Diabetes Center, University of California, San Francisco, CA, USA  California Pacific Medical Center, San Francisco, CA, USA.
Transplant International (Impact Factor: 3.16). 09/2012; 25(12). DOI: 10.1111/j.1432-2277.2012.01565.x
Source: PubMed

ABSTRACT This study examined the effect of thymoglobulin induction therapy on leukocyte population dynamics in kidney transplant patients. Patients receiving standard immunosuppression were compared with those who received additional thymoglobulin at the time of kidney transplantation. Thymoglobulin induction led to an immediate and significant decrease of all T cells and NK cells, but not B cells or monocytes. CD8(+) T cells recovered to near pretransplant level by 4 weeks post-transplant. CD4(+) T cells remained at less than 30% of pretransplant level for the entire study period of 78 weeks. Both CD4(+) and CD8(+) T cells showed reduced cytokine production after recovery. Deletion of CD4(+) FOXP3(+) HELIOS(+) regulatory T cells (Tregs) was less profound than that of CD4(+) FOXP3(-) cells, thus the relative percentage of Tregs elevated significantly when compared with pretransplant levels in thymoglobulin-treated patients. In contrast, the percentages of Tregs and their expression of FOXP3 in the standard immunosuppression group decreased steadily and by 12 weeks after transplant the average percentage of Tregs was 56% of the pretransplant level. Thus, thymoglobulin-induced deletion of T cells led to significant and long-lasting alterations of the T-cell compartment characterized by a preservation of Tregs and long-lasting reduction in CD4(+) , and potentially pathogenic, T cells.

Download full-text


Available from: Qizhi Tang, Jan 13, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Foxp3+ regulatory T cells (Tregs) play a pivotal role in control of autoimmunity and pathologic immune responses. Helios, the Ikarus family transcription factor, binds to the Foxp3 promoter, stabilizing its expression and is expressed in 70% of peripheral Tregs of healthy individuals. This frequency is altered during malignancy, infection and autoimmunity, although the mechanisms that control proliferation and relative numbers of Helios+/- Tregs remain largely unknown. Using a T cell-monocyte in vitro stimulation assay, we now show that proliferation of Helios+ Tregs is inhibited by CD16+ monocyte subset. Antibody blocking with anti-IL-12 reversed this inhibition, whereas addition of IL-12 suppressed Helios+ Treg expansion, indicating that CD16+ monocyte control of Helios+ Treg numbers is mediated through IL-12. In contrast, proliferation of Helios- Tregs, which express higher levels of TNFRII, was suppressed by TNF-α, while anti-TNF-α and anti-TNFRII reversed the inhibition. CD16- monocyte subset was mainly responsible for TNF-α mediated control of Helios- Treg expansion. Altogether, these data suggest a differential role for monocyte subsets in control of Helios +/- Treg development that is mediated by distinct inflammatory cytokines and as such may important implications for understanding the pathogenesis as well as control of chronic inflammatory and autoimmune diseases.
    Blood 01/2013; 121(13). DOI:10.1182/blood-2012-11-469122 · 10.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: T regulatory cells (Tregs) play a critical role in the immunologic tolerance to the graft in transplantation. Thus, due to their immunosuppressive capability, ex vivo expanded Tregs may be used as a cellular therapy and an attractive novel strategy to control chronic rejection and eliminate need for lifelong pharmacological immunosuppression. Since Treg therapy is still in its infancy, initially Tregs still need to be applied in combination with pharmacological agents to prevent rejection. Fortunately, some of the medications have been shown to enhance the function and number of Tregs. In the clinic, different immunosuppressive regimens are used for individual patients for different types of organ transplantation. In this review, we present the most commonly used pharmacological agents for immunosuppression and discuss how they affect the Treg population. It is extremely difficult to dissect the effect of single agent on Tregs population in clinical settings since usually the combination of several medications is applied at the same time for graft protection. Nevertheless, experimental and clinical data indicate that thymoglobulin as immunosuppressive induction and mTOR inhibitors as immunosuppressive maintenance agents have the most beneficial effect on Treg population in the blood. Among supplemental agents promoting Tregs, anti-TNFα preparations have been in clinical use (in autoimmune diseases) for many years, so they are optimal candidates for testing in transplant settings in combination with Treg based cellular therapy.
    International immunopharmacology 03/2013; DOI:10.1016/j.intimp.2013.02.015 · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past decade, much has been learnt and much more to discover about Foxp3(+) regulatory T cells (Tregs). Initially, it was thought that Tregs were a unique entity that originates in the thymus. It is now recognized that there is a fraternal twin sibling that is generated in the periphery. The difficulty is in the distinction between these two subsets. The ability to detect, monitor, and analyze these two subsets in health and disease will provide invaluable insights into their functions and purposes. The plasticity and mechanisms of action can be unique and not overlapping within these subsets. Therefore, the therapeutic targeting of a particular subset of Tregs might be more efficacious. In the past couple of years, a vast amount of data have provided a better understanding of the cellular and molecular components essential for their development and stability. Many studies are implicating their preferential involvement in certain diseases and immunologic tolerance. However, it remains controversial as to whether any phenotypic markers have been identified that can differentiate thymic versus peripheral Tregs. This review will address the validity and controversy regarding Helios, Lap/Garp and Neuropilin-1 as markers of thymic Tregs. It also will discuss updated information on distinguishing features of these two subsets and their critical roles in maternal-fetal tolerance and transplantation.
    Frontiers in Immunology 08/2013; 4:253. DOI:10.3389/fimmu.2013.00253
Show more